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The target of rapamycin (TOR) is a conserved Ser/Thr kinase that regulates cell growth 
and metabolism in response to environmental cues. Here, highlighting contributions from 
studies in model organisms, we review mammalian TOR complexes and the signaling 
branches they mediate. TOR is part of two distinct multiprotein complexes, TOR complex 
1 (TORC1), which is sensitive to rapamycin, and TORC2, which is not. The physiological 
consequences of mammalian TORC1 dysregulation suggest that inhibitors of mammalian 
TOR may be useful in the treatment of cancer, cardiovascular disease, autoimmunity, and 
metabolic disorders.Introduction
In the 1970s, a soil sample from Easter Island (known as 
Rapa Nui in the local language) was found to contain a bac-
terial strain, Streptomyces hygroscopicus, that produced a 
potent antifungal metabolite. This metabolite was purified 
and found to be a macrocyclic lactone, which was named 
rapamycin after its place of discovery. Later, rapamycin 
was found to inhibit proliferation of mammalian cells and to 
possess immunosuppressive properties. These intriguing 
observations prompted further investigation into the mode 
of action of rapamycin.
The target of rapamycin (TOR) was originally identified 
by mutations, TOR1-1 and TOR2-1, that confer resistance 
to the growth inhibitory properties of rapamycin, in the bud-
ding yeast Saccharomyces cerevisiae (Heitman et al., 1991). 
This study also demonstrated that rapamycin requires an 
intracellular cofactor, the peptidyl-prolyl cis/trans isomer-
ase FKBP12, for toxicity. Rapamycin forms a complex with 
FKBP12, and this complex then binds to and inhibits TOR. Subsequent biochemical studies in mammalian cells led to 
the identification and cloning of the mammalian target of 
rapamycin, mTOR (also known as FRAP, RAFT, RAPT, or 
SEP; reviewed in Fingar and Blenis, 2004; Hay and Sonen-
berg, 2004). To date, every eukaryote genome examined 
(including yeasts, algae, slime mold, plants, worms, flies, 
and mammals) contains a TOR gene. Unlike yeast, which 
in some cases possess two TOR genes, higher eukaryotes 
possess only a single TOR gene (Crespo and Hall, 2002; 
Lee et al., 2005; Crespo et al., 2005).
Eukaryote TORs are large proteins ( 280 kDa) that share 
40%–60% identity in their primary sequence and belong 
to a group of kinases known as the phosphatidylinositol 
kinase-related kinase (PIKK) family. PIKK family members 
contain a carboxy-terminal serine/threonine protein kinase 
domain that resembles the catalytic domain of phosphati-
dylinositol 3-kinases (PI3Ks) and PI4Ks. Amino-terminal to 
the kinase domain in TOR is the FKBP12-rapamycin binding 
domain (FRB; Figure 1). Single amino acid substitutions in Figure 1. TOR Complex 1 (TORC1) and 
TOR Complex 2 (TORC2) of S. cerevisiae
Depicted are TOR-associated proteins (KOG1, 
TCO89, LST8, AVO1–3, and BIT61) and the do-
mains found in TOR (HEAT, FAT, FRB, Kinase, 
and FATC). Both TORC1 and TORC2 are mul-
timers, likely dimers. TORC1 mediates the ra-
pamycin-sensitive signaling branch that couples 
growth cues to the accumulation of mass. Stim-
uli that positively regulate TORC1 and TORC1 
outputs that promote the accumulation of mass 
are depicted with black arrows. Inputs that neg-
atively regulate TORC1 and the stress- and star-
vation-induced processes that TORC1 regulates 
negatively are depicted with red bars. TORC2 
signaling is rapamycin insensitive and is required 
for the organization of the actin cytoskeleton. 
Upstream regulators of TORC2 are not known.Cell 124, February 10, 2006 ©2006 Elsevier Inc. 471
this domain yield TOR proteins (such as TOR1-1 and TOR2-
1) that are no longer bound and inhibited by the FKBP12-
rapamycin complex. Located amino-terminal to the FRB 
domain and carboxy-terminal to the kinase domain are the 
FAT (FRAP, ATM, and TTRAP) and FATC domains, respec-
tively. These domains are found in all PIKKs and always 
together, suggesting that they may interact. The amino- 
terminal half of TOR contains tandem HEAT repeats that 
may form an extended superhelical array with large inter-
faces for protein-protein interactions.
Physiological Roles for TOR
TOR Is a Central Controller of Cell Growth
Cell growth (accumulation of mass) is an extensively coor-
dinated process that is regulated in both time and space. 
When nutrients and other appropriate growth stimuli 
are present, cells upregulate macromolecular synthesis 
and thereby increase in size and mass. Conversely, cells 
respond to nutrient limitation or other types of stress by 
restraining macromolecular synthesis and enhancing turn-
over of excess mass. Cell growth can also be subject to 
spatial constraints, as evidenced by the fact that many 
cells do not grow isotropically but rather deposit new mass 
at discrete loci. Studies in yeast demonstrated that TOR 
performs two essential functions in this organism; one reg-
ulates when a cell grows and the second regulates where a 
cell grows (reviewed in Loewith and Hall, 2004).
When growth conditions are favorable, TOR is active 
and yeast cells maintain a robust rate of ribosome biogen-
esis, translation initiation, and nutrient import. However, 
rapidly growing yeast cells treated with rapamycin, starved 
for nitrogen, or depleted of both TOR1 and TOR2 dramati-
cally downregulate general protein synthesis, upregulate 
macroautophagy (the random sequestration and delivery 
of cytoplasm to the lysosome/vacuole), and activate sev-
eral stress-responsive transcription factors. Thus, when 
growth conditions permit, rapamycin-sensitive TOR signal-
ing promotes anabolic processes and antagonizes cata-
bolic processes. Many of these rapamycin-sensitive read-
outs of TOR are conserved in mammals.
TOR2, but not TOR1, functions further to regulate spatial 
aspects of yeast cell growth (Loewith and Hall, 2004). In 
budding yeast, the majority of growth occurs in the bud (the 
daughter cell). To accomplish this, yeast cells polarize their 
actin cables and patches toward the bud. This polarization 
of the actin cytoskeleton facilitates trafficking of macromol-
ecules from the mother cell to the bud for deposition. TOR2 
activity is important for this cell cycle-dependent polariza-
tion of the actin cytoskeleton. Curiously, the ability of TOR2 
to regulate these spatial aspects of yeast cell growth is 
insensitive to rapamycin. The rapamycin-insensitive ability 
of TOR to regulate organization of the actin cytoskeleton is 
also conserved in mammals.
Metazoan TOR Is Essential for Growth during 
Early Development
Deletion of CeTOR in the nematode worm Caenorhabditis 
elegans or of dTOR in the fruit fly Drosophila melanogaster 
causes developmental arrests that share some features 472 Cell 124, February 10, 2006 ©2006 Elsevier Inc.with the arrests observed in starved larvae (Long et al., 
2002; Oldham et al., 2000; Zhang et al., 2000). Recent 
studies have shown that dTOR affects the timing of neu-
ronal cell differentiation. Hyperactivation of dTOR signal-
ing leads to accelerated differentiation, whereas inhibition 
of dTOR signaling retards differentiation (Bateman and 
McNeill, 2004). Thus, similar to yeast TOR, dTOR also reg-
ulates temporal aspects of cell growth. Interestingly, abla-
tion of dTOR in the fat body (the fly equivalent of liver and 
adipose tissue) results in a systemic defect in larval growth 
(Colombani et al., 2003). Thus, in addition to controlling 
growth of the cell in which it resides, dTOR can also influ-
ence growth of distant cells and organs during develop-
ment via a humoral mechanism.
TOR is also required for development in mice. Homo-
zygous mTOR−/− embryos resemble embryos starved of 
amino acids ex vivo and die shortly after implantation due 
to impaired cell proliferation in both embryonic and extra-
embryonic compartments (Gangloff et al., 2004; Martin 
and Sutherland, 2001; Murakami et al., 2004). Exposure 
of early mouse embryos to rapamycin also arrests cell 
proliferation (Martin and Sutherland, 2001), indicating 
that rapamycin-sensitive mTOR function is essential dur-
ing this stage of development. These results suggest that 
metazoan TOR coordinates growth and development in 
response to nutritional cues.
TOR Influences Memory and Aging in Adults
Rapamycin-sensitive mTOR function appears to be less 
important in adults because systemic administration of 
rapamycin to adult humans results in relatively mild side 
effects. However, rapamycin treatment has been found to 
antagonize long-term consolidation of a cerebral cortex-
dependent form of memory in gerbils (Tischmeyer et al., 
2003) and synapse-specific long-term facilitation in Aplysia 
californica (Casadio et al., 1999). Also, partial inhibition of 
TOR function in yeast, worms, and flies results in a signifi-
cant increase in the life span of these organisms, possibly 
by mimicking calorie restriction (reviewed in Martin and Hall, 
2005, and Kaeberlein et al., 2005). Although links between 
mTOR signaling and mammalian longevity have not yet 
been reported, it appears that TOR signaling plays different 
roles in development and adulthood in metazoans. During 
development, TOR primarily controls growth, whereas in 
the adult, where there is relatively little growth, TOR controls 
aging and other aspects of nutrient-related physiology.
Two TOR Complexes
TORC1 Is Sensitive to Rapamycin and Regulates 
Temporal Aspects of Cell Growth
As described above, genetic studies in yeast demon-
strated that rapamycin-sensitive TOR signaling regulates 
when a cell grows, and rapamycin-insensitive TOR signal-
ing regulates where a cell grows. Biochemical purification 
of TOR1 and TOR2 from yeast led to the identification of 
two distinct TOR protein complexes, TORC1 and TORC2, 
which account for the differential sensitivity of TOR signal-
ing to rapamycin (Loewith et al., 2002). TORC1 (Figure 1; 
Table 1) contains KOG1, TCO89, LST8, and either TOR1 or 
Table 1. Components of TORC1 and TORC2 in Various Eukaryotes
S. cerevisiae S. pombe Dictyostelium A. thaliana C. elegans Drosophila Mammals
TORC1
TOR1 or TOR2 Tor1p or Tor2p Dd-TOR AtTOR CeTOR dTOR mTOR
KOG1 Mip1p JC1V2_0_00963a AtRaptor1A AtRaptor1B Daf-15 dRaptor raptor
LST8 Wat1p/Pop3p Dd-LST8 At3g18140d At2g22040d C10H11.8b CG3004c mLST8
TCO89 — — — — — —
TORC2
TOR2 Tor1p or Tor2p? Dd-TOR AtTOR CeTOR dTOR mTOR
AVO1 Sin1p? Rip3 — — — hSIN1?
AVO2 — — — — — —
AVO3 Ste20p Pia — — dRictor rictor
LST8 Wat1p/Pop3p Dd-LST8 At3g18140d At2g22040d C10H11.8b CG3004c mLST8
BIT61 — — — — — —
Listed are the protein components of S. cerevisiae TORC1 and TORC2 and known homologs in other species in which TOR has been 
at least partly characterized. Proteins indicated in bold have been shown to associate in a TORC1- or TORC2-like complex. The finding 
that Tor1p and Tor2p interact with Mip1p in S. pombe is unpublished (M. Yamamoto, personal communication). It is not known whether 
the Tor in S. pombe TORC2 is Tor1p or Tor2p. It is questionable whether Sin1p (S. pombe) and hSIN1 (mammals) are components of 
TORC2 as they are only weakly homologous to AVO1. —, no homolog found.
adictyBase gene name.
bWormBase sequence name.
cFlyBase gene name.
dTIGR locus name.TOR2 (Loewith et al., 2002; Reinke et al., 2004). FKBP12-
rapamycin binds TORC1, and TORC1 disruption mimics 
rapamycin treatment, suggesting that TORC1 mediates the 
rapamycin-sensitive temporal control of cell growth (Loe-
with et al., 2002).
Like TOR, KOG1 and LST8 (but not TCO89) have obvi-
ous mammalian sequence homologs, raptor and mLST8 
(also known as GβL), respectively. mTOR, raptor, and 
mLST8 associate in a complex, mTORC1 (Figure 2; Table 
1; Hara et al., 2002; Kim et al., 2002, 2003; Loewith et 
al., 2002). As discussed below, mTORC1 also appears 
to regulate temporal aspects of cell growth. mTORC1 is 
bound by FKBP12-rapamycin, and mTORC1 kinase activity 
is abrogated by FKBP12-rapamycin both in vivo and in vitro 
(Hara et al., 2002; Jacinto et al., 2004; Kim et al., 2002; 
Sarbassov et al., 2004).
The individual functions of mTORC1 components are 
poorly understood. Raptor is a large protein (150 kDa) 
containing a highly conserved, amino-terminal domain 
followed by several HEAT repeats and seven carboxy- 
terminal WD40 repeats (Hara et al., 2002; Kim et al., 2002). 
The domains in raptor and mTOR that interact have been 
difficult to map, suggesting multiple contact sites between 
these two proteins. Knockdown of the mammalian, worm, 
and fly versions of KOG1/raptor phenocopies rapamycin 
treatment and/or depletion of TOR in these organisms, 
indicating that raptor functions positively in mTOR signal-
ing (Hara et al., 2002; Kim et al., 2002; Sarbassov et al., 
2004). A number of groups have proposed that raptor acts 
as an adaptor to recruit substrates to mTOR (Choi et al., 2003; Hara et al., 2002; Nojima et al., 2003; Schalm et 
al., 2003), whereas Kim et al. (2002) have suggested that 
upstream signals regulate the raptor-mTOR interaction and 
thereby the activity of mTORC1. The mechanism by which 
FKBP12-rapamycin binding inhibits mTORC1 is not known 
and may indeed involve more than one mechanism. Under 
some experimental conditions, FKBP12-rapamycin dis-
sociates raptor-mTOR (Kim et al., 2002), suggesting that 
FKBP12-rapamycin blocks access to substrates. This may 
be a common mechanism of mTORC1 inhibition because 
farnesylthiosalicyclic acid also dissociates raptor-mTOR 
and inhibits mTORC1 activity in vivo (McMahon et al., 
2005). Jacinto et al. (2004) have observed that FKBP12-
rapamycin inhibits mTORC1 autophosphorylation, sug-
gesting that FKBP12-rapamycin inhibits intrinsic mTORC1 
kinase activity rather than, or in addition to, access to an 
extrinsic substrate.
mLST8 is a 36 kDa protein that has seven WD40 repeats. 
mLST8 binds to the kinase domain of mTOR, and knock-
down studies in mammals and yeast suggest that mLST8 
also functions positively in mTORC1 signaling (Chen and 
Kaiser, 2003; Kim et al., 2003; Loewith et al., 2002). How-
ever, the precise role of mLST8 is not known. Kim et al. 
(2003) have suggested that mLST8 functions to receive 
upstream signals that impinge on mTORC1, whereas Chen 
and Kaiser (2003) have proposed that LST8 in yeast regu-
lates signal outputs from TORC1. LST8 is necessary for 
full catalytic activity of TOR (Wullschleger et al., 2005), and 
overexpression of mLST8 stimulates mTOR kinase activity 
(Kim et al., 2003).Cell 124, February 10, 2006 ©2006 Elsevier Inc. 473
TORC2 Is Insensitive to Rapamycin and Regulates 
Spatial Aspects of Cell Growth
Yeast TORC2 contains AVO1, AVO2, AVO3, BIT61, LST8, 
and TOR2, but not TOR1 (Figure 1; Table 1; Loewith et 
al., 2002; Reinke et al., 2004). FKBP12-rapamycin does 
not bind to TORC2, and TORC2 disruption mimics TOR2 
depletion, suggesting that TORC2 mediates the rapamy-
cin-insensitive spatial control of cell growth (Loewith et al., 
2002).AVO1 and AVO3 bind cooperatively to the amino- 
terminal HEAT repeats in TOR2 and are required for TORC2 
integrity (Figure 1). AVO2 is a nonessential peripheral protein 
associated with AVO1 and AVO3 and may serve to recruit 
substrates to TOR2 (Audhya et al., 2004; Wullschleger et 
al., 2005). AVO1 and AVO3 are phosphorylated on many 
sites in vivo and are autophosphorylated by TORC2 in vitro 
(Wullschleger et al., 2005). However, the significance of 
these phosphorylation events is not known. TORC2 kinase 
activity is not required for complex stability.
TORC2 is a multimeric supercomplex that is likely a 
TORC2-TORC2 dimer assembled via a TOR2-TOR2 inter-
action (Figure 1; Wullschleger et al., 2005). Multimerization 
may be a general property of TOR complexes. Yeast and 
mammalian TORC1 are also multimeric (Wullschleger et al., 
2005; T. Maeda, personal communication), as is Drosoph-
ila TOR (Zhang et al., 2005). The elegant genetic study of 
Zhang et al. (2005) demonstrated that dTOR is multimeric, 
but did not determine whether the multimerization corre-
sponded to dTORC1 or dTORC2. Multimerization may play 
a role in the regulation of TORC kinase activity because 
multimeric TORC2 appears to be a more active kinase than 
monomeric TORC2 (Wullschleger et al., 2005).
Like TORC1, TORC2 is conserved. 
Dictyostelium discoideum TORC2 con-
tains Dd-TOR, Dd-LST8, RIP3, and Pia-
nissimo, orthologs of the yeast TORC2 
components TOR2, LST8, AVO1, and 
AVO3, respectively (Lee et al., 2005; 
Table 1). Mutations in Dd-LST8, RIP3, 
and PIA exhibit a common set of pheno-
types including reduced cell polarity and 
a loss of chemotaxis speed and direc-
tionality, suggesting that regulation of the 
actin cytoskeleton and cell polarity is a 
conserved function of TORC2.
Mammalian TORC2 (mTORC2) contains mTOR, rictor, 
and mLST8, but not raptor (Table 1; Figure 2; Jacinto et 
al., 2004; Sarbassov et al., 2004). Searches of mamma-
lian genome databases indicated that there is a mam-
malian protein, hSIN, which has limited homology with 
AVO1. hSIN1 shares a similar tissue expression pattern 
with mTOR and mLST8, but efforts to demonstrate a 
stable interaction between mTOR and hSIN1 have been 
unsuccessful (Loewith et al., 2002). Thus, a role for hSIN1 
in mTOR signaling remains uncertain. AVO2 and BIT61 
appear to be unique to yeast.
Rictor  (also known as mAVO3) is a large protein ( 200 
kDa) but contains no obvious catalytic motifs. Knockdown 
of mTOR or rictor (but not raptor) results in loss of both actin 
polymerization and cell spreading (Jacinto et al., 2004; 
Sarbassov et al., 2004), which is consistent with results 
from studies in yeast and Dictyostelium. Also consistent 
with studies in model organisms is the observation that 
mTORC2 is neither bound by FKBP12-rapamycin nor does 
FKBP12-rapamycin affect mTORC2 in vitro kinase activity 
(Jacinto et al., 2004; Sarbassov et al., 2004).
Upstream Regulators of the TOR Signaling 
Network
TOR integrates various signals to regulate cell growth. 
Four major inputs have been implicated in TOR signaling: 
growth factors, nutrients, energy, and stress.
Growth Factors
The mTOR pathway responds to growth factors via the 
PI3K pathway (Figure 2). Binding of insulin or insulin-like 
growth factors (IGFs) to their receptors leads to recruit-
Figure 2. Model of the mTOR Signaling 
Network in Mammalian Cells
The mTOR signaling network consists of two 
major branches, each mediated by a specific 
mTOR complex (mTORC). Rapamycin-sensitive 
mTORC1 controls several pathways that collec-
tively determine the mass (size) of the cell. Ra-
pamycin-insensitive mTORC2 controls the actin 
cytoskeleton and thereby determines the shape of 
the cell. mTORC1 and possibly mTORC2 respond 
to growth factors (insulin/IGF), energy status of the 
cell, nutrients (amino acids), and stress. mTORC1 
(and likely mTORC2) are multimeric, although are 
drawn as monomers. Arrows represent activation, 
whereas bars represent inhibition. 474 Cell 124, February 10, 2006 ©2006 Elsevier Inc.
ment and phosphorylation of the insulin receptor substrate 
(IRS), and subsequent recruitment of PI3K. PI3K bound to 
IRS converts phosphatidylinositol-4,5-phosphate (PIP2) 
in the cell membrane to phosphatidylinositol-3,4,5-phos-
phate (PIP3). PIP3 accumulation is antagonized by the lipid 
phosphatase PTEN. PIP3 corecruits PDK1 and Akt to the 
membrane, resulting in the phosphorylation and activation 
of Akt by PDK1. mTOR is wired to the PI3K pathway through 
the tuberous sclerosis proteins TSC1 (hamartin) and TSC2 
(tuberin). TSC1 and TSC2 act as a heterodimer that nega-
tively regulates mTOR signaling. TSC2 is phosphorylated 
and functionally inactivated by Akt in response to insulin 
(reviewed in Manning, 2004). However, the significance 
of TSC2 phosphorylation by Akt may vary depending on 
physiological context. In Drosophila, for example, a TSC2 
variant that cannot be phosphorylated by Akt rescues the 
lethality of a TSC2 mutant (Dong and Pan, 2004), indicat-
ing that Akt phosphorylation of TSC2 is not essential at 
least during fly development. As discussed below, TSC2 is 
also phosphorylated and regulated by other kinases.
How does TSC1-TSC2 regulate mTORC1? TSC2 acts as 
a GAP (GTPase-activating protein) for the small GTPase 
Rheb (reviewed in Li et al., 2004). Rheb binds directly to 
the kinase domain in mTOR and activates mTOR in a GTP-
dependent manner (Long et al., 2005a). However, Rheb 
binding to mTOR is independent of the guanyl nucleotide, 
and nucleotide-free Rheb inhibits mTOR activity (Long et 
al., 2005a; Smith et al., 2005). Long et al. (2005a) sug-
gest that GTP loading of Rheb, rather than mediating 
mTORC1 recruitment, enables Rheb to induce a confor-
mational change in mTORC1 leading to mTORC1 activation 
and phosphorylation of downstream targets. In S. pombe, 
Rheb binds to TOR in a GTP-dependent manner, suggest-
ing that, in this case, GTP loading mediates effector recruit-
ment (Urano et al., 2005). Although there is agreement that 
Rheb binds TOR, consensus is lacking on whether GTP 
loading of Rheb is required for mTOR binding or for a sub-
sequent mTOR-activation step.
Nutrients
Nutrients, especially amino acids, regulate mTORC1 sig-
naling. Amino acid starvation, in particular the absence 
of leucine, results in a rapid dephosphorylation of the 
mTORC1 effectors S6K1 and 4E-BP1, whereas readdition 
of amino acids restores S6K1 and 4E-BP1 phosphoryla-
tion in an mTORC1-dependent manner (Hay and Sonen-
berg, 2004). Amino acids have been proposed to activate 
mTORC1 via inhibition of TSC1-TSC2 or, alternatively, via 
stimulation of Rheb. Gao et al. (2002) have demonstrated 
that inactivation of TSC2 renders cells resistant to amino 
acid withdrawal, suggesting that the amino acids signal 
via TSC1-TSC2. Other studies have proposed a model in 
which amino acids signal to mTORC1 independently of 
TSC2. Amino acid withdrawal still downregulates mTORC1 
signaling in TSC2-deficient cells (Smith et al., 2005), and 
overexpression of Rheb in Drosophila and mammalian 
cells allows TORC1 signaling in the absence of amino acids 
(Saucedo et al., 2003; Garami et al., 2003). Furthermore, 
the binding of Rheb to mTOR is regulated by amino acid sufficiency, whereas GTP charging of Rheb is independent 
of amino acids (Long et al., 2005b). These studies sug-
gest that the amino acid signal impinges on Rheb. How-
ever, others failed to detect amino acid-regulated binding 
of Rheb to mTOR (Smith et al., 2005). Recent studies sug-
gest that hVPS34, a class III PI3K (converts phosphati-
dylinositol to phosphatidylinositol-3-phosphate), signals 
amino acid availability to mTORC1 independently of the 
TSC1-TSC2/Rheb axis (Byfield et al., 2005; Nobukuni et 
al., 2005). TORC1 in S. cerevisiae responds to nutrients 
despite the absence of functional Rheb and TSC ortho-
logs in this organism, and withdrawal of amino acids in 
mammalian cells alters the binding of raptor to mTOR (Kim 
et al., 2002). These latter observations may suggest that 
amino acids are sensed by mTORC1 directly. Clearly, the 
mechanism(s) by which nutrient status is communicated to 
mTORC1 requires further study.
Energy
Cell growth (the accumulation of cell mass) depends 
on a high rate of protein synthesis and consequently 
requires a high level of cellular energy. mTORC1 senses 
the energy status of a cell through AMP-activated protein 
kinase (AMPK). AMPK is activated in response to low cel-
lular energy (high AMP/ATP ratio). Activated AMPK down-
regulates energetically demanding processes like protein 
synthesis and stimulates ATP-generating processes such 
as fatty acid oxidation. Activation of AMPK by AICAR, an 
AMP analog, inhibits mTORC1-dependent phosphoryla-
tion of S6K1 and 4E-BP1. Activated AMPK directly phos-
phorylates TSC2 and thereby enhances its GAP activity, 
leading to the inhibition of mTORC1 signaling (Inoki et al., 
2003). The tumor suppressor LKB1 has been identified 
as an upstream kinase for AMPK, suggesting that LKB1 
is linked to the TSC-mTORC1 signaling pathway. Indeed, 
LKB1 mutant cells exhibit hyperactive mTORC1 signaling 
(Corradetti et al., 2004; Shaw et al., 2004). Thus, upon 
energy deprivation LKB1 in conjunction with AMP activates 
AMPK, which in turn phosphorylates and activates TSC2, 
resulting in the inhibition of mTORC1.
Regulation of the cellular energy supply may also be a 
mechanism to activate mTORC1. Hahn-Windgassen et al. 
(2005) have suggested that Akt activates mTORC1 not only 
by direct phosphorylation of TSC2, but also by regulation 
of cellular energy. According to this model, Akt maintains a 
high ATP level that causes a decrease in the AMP/ATP ratio 
that in turn inhibits AMPK-mediated phosphorylation and 
activation of TSC2. The means by which Akt maintains a 
high energy level involves, at least in part, the maintenance 
of nutrient uptake (Edinger and Thompson, 2002).
Stress
Cells respond to environmental stress, such as hypoxia, 
or low energy by downregulating energy-demanding pro-
cesses and arresting growth. TOR has been demonstrated 
to play a role in the response to stress. Upon hypoxia, 
TOR signaling is inhibited and protein synthesis is thereby 
downregulated. Insights into the regulation of mTORC1 
upon hypoxia have been provided by studies in Drosophila 
and mammalian cells (Brugarolas et al., 2004; Reiling and Cell 124, February 10, 2006 ©2006 Elsevier Inc. 475
Hafen, 2004). Hypoxia is transduced to mTORC1 via the 
two homologous proteins REDD1 and REDD2 (Scylla and 
Charybdis in Drosophila). The expression of REDD is upreg-
ulated upon hypoxia by the transcription factor HIF1. REDD 
acts downstream of Akt and upstream of TSC1-TSC2 to 
inhibit mTORC1 signaling. Furthermore, REDD acts inde-
pendently of the LKB1-AMPK signaling branch to down-
regulate mTORC1. However, hypoxia and the LKB1-AMPK 
pathway are likely interrelated, as prolonged hypoxia would 
eventually lead to ATP depletion and activation of AMPK.
Other stress signals that downregulate mTOR signal-
ing include DNA damage and reducing conditions. p53 
activated upon DNA damage inhibits mTOR activity via 
the AMPK-TSC2 signaling pathway (Feng et al., 2005). 
A reducing environment inhibits mTORC1 possibly via a 
redox sensor in the FATC domain of mTOR (Dames et al., 
2005; Sarbassov and Sabatini, 2005).
TSC2 is also phosphorylated by kinases other than Akt 
and AMPK. The Ras/MAPK pathway targets TSC2, as evi-
denced by the observation that expression of an activated 
allele of ras induces phosphorylation of TSC2 (Roux et 
al., 2004). Furthermore, loss-of-function mutations in the 
NF1-encoded tumor suppressor neurofibromin, a Ras-
GAP, deregulate TSC2 and ultimately cause constitutive 
mTORC1 signaling (Johannessen et al., 2005). Ras acti-
vates the Raf-MEK1/2-Erk1/2 cascade. Activated Erk1/2 
directly phosphorylates TSC2 at sites that differ from the 
Akt target sites, thereby causing functional inactivation of 
the TSC1-TSC2 complex (Ma et al., 2005a). The MAPK-acti-
vated kinase RSK1 also phosphorylates TSC2 at a unique 
site (Roux et al., 2004). RSK1-mediated phosphorylation 
of TSC2 inhibits the TSC1-TSC2 complex and thereby 
increases mTORC1 signaling toward S6K1. In addition, a 
PKC-dependent TSC2 regulatory pathway has been pro-
posed (Ballif et al., 2005). Thus, the PI3K/Akt and Ras/Erk 
signaling pathways converge on TSC1-TSC2, resulting in 
TSC2 inactivation and ultimately mTORC1 activation. This 
model implies that both PI3K/Akt and Ras/Erk regulate 
translation via mTORC1 signaling.
Several additional proteins have been demonstrated 
to interact with the TSC proteins and to modulate the 
activity of TSC1-TSC2. In Drosophila, the protein Melted 
interacts with TSC1 and thereby recruits TSC1 to the cell 
membrane. Association with Melted brings TSC1 in prox-
imity to membrane-associated upstream signaling com-
ponents such as Akt (Teleman et al., 2005). Melted also 
mediates binding of the transcription factor FOXO to the 
membrane in an insulin-dependent manner. Like TSC2, 
FOXO transcription factors are phosphorylated and inhib-
ited by Akt. Consistent with the above findings, melted 
mutant flies exhibit reduced TOR activity and increased 
FOXO activity and resemble nutrient-starved animals. 
Another TSC1-TSC2-interacting protein is FIP200 (Gan 
et al., 2005). FIP200 interacts with TSC1 and thereby 
inhibits the function of TSC1-TSC2. The role of FIP200 
in controlling TSC1-TSC2 function is restricted to nutrient 
stimulation. FIP200 is also involved in regulation of FAK 
(focal adhesion kinase), suggesting that FIP200 may link 476 Cell 124, February 10, 2006 ©2006 Elsevier Inc.cell adhesion to the regulation of cell growth.
In summary, several upstream signaling cues, growth 
factors, energy, stress, and possibly amino acids con-
verge on TSC1-TSC2 to regulate mTORC1 signaling. It is 
important to note that the effect of these upstream signals 
on mTOR signaling has been studied only in the context 
of mTORC1. The recent identification of mTORC2 raises 
the question of whether mTORC2 is similarly regulated. 
mTORC2 is involved in the organization of the actin cyto-
skeleton (Jacinto et al., 2004; Sarbassov et al., 2004), and 
TSC1-TSC2 regulates cell adhesion and migration (Astrini-
dis et al., 2002), suggesting that mTORC2 might also act 
downstream of TSC1-TSC2. Whether TSC1-TSC2 signals 
through mTORC2 to the actin cytoskeleton or through a 
different pathway remains to be elucidated. Despite the 
recent advances in mammals and Drosophila, upstream 
regulators of TOR in yeast remain elusive. S. cerevisiae 
does not contain TSC1 and TSC2 orthologs, indicating 
that upstream signaling cues may be sensed differently in 
budding yeast.
Downstream Targets of the TOR Signaling 
Network
TOR signaling plays a role in various growth-related pro-
cesses in yeast and in higher eukaryotes. The best stud-
ied targets of TOR in mammalian cells are the translation 
regulators S6K1 and 4E-BP1. However, it is important to 
emphasize that, like TOR in yeast, mTOR controls several 
additional growth-related processes.
Translation
mTORC1 regulates translation via S6K1 and 4E-BP (Hay and 
Sonenberg, 2004; Tee and Blenis, 2005). S6K1 belongs to 
the AGC family of protein kinases and requires phosphory-
lation at two sites for its full activation, a site in a C-termi-
nal hydrophobic motif and a site in the T loop of the kinase 
domain. mTORC1 mediates phosphorylation of Thr389 
within the hydrophobic motif, whereas PDK1 is responsible 
for phosphorylation of the T loop. Activated S6K1 phos-
phorylates the 40S ribosomal protein S6, and this was com-
monly thought to lead to increased translation of a subset of 
mRNAs that contain a 5′ tract of oligopyrimidine (TOP). The 
5′TOP mRNAs encode components of the translation appa-
ratus, such as ribosomal proteins and elongation factors, 
and are predicted to account for 15%–20% of total cellular 
mRNA. Thus, via increased translation of 5′TOP mRNAs, 
S6K1 would upregulate general translation capacity. How-
ever, this model has now lost favor due to the recent find-
ings that translation of 5′TOP mRNAs does not depend on 
S6K (S6K1 and S6K2) activity nor on S6 phosphorylation 
(Pende et al., 2004; Ruvinsky et al., 2005). It remains to be 
determined how mTORC1 controls 5′TOP mRNAs. It also 
remains to be determined if and how S6K controls transla-
tion other than via regulation of elongation factor 2 kinase 
(eEF2K; Wang et al., 2001). Interestingly, Holz et al. (2005) 
have shown that the eukaryotic translation initiation factor 
eIF3 acts as a scaffold for mTORC1 and S6K1. mTORC1 
promotes cap-dependent translation initiation through 
phosphorylation of eIF4E binding proteins (4E-BPs). Phos-
phorylated 4E-BP1 releases eIF4E, which is then free to 
associate with eIF4G to stimulate translation initiation.
mTORC1 associates with S6K1 and 4E-BP1 via an 
interaction between raptor and a TOR signaling (TOS) 
motif in S6K and 4E-BP (Choi et al., 2003; Nojima et al., 
2003; Schalm et al., 2003). The TOS motif is a conserved 
five amino acid segment found in the N terminus of S6K1 
(Phe-Asp-Ile-Asp-Leu) and in the C terminus of 4E-BP1 
(Phe-Glu-Met-Asp-Ile) and is necessary for the phos-
phorylation of these proteins by mTORC1 in vivo (Schalm 
and Blenis, 2002).
Ribosome Biogenesis
Ribosome biogenesis accounts for a large segment of 
total energy consumption by the cell. A cell must there-
fore have a mechanism to tightly control ribosomal biogen-
esis in response to the availability of energy and building 
blocks. Studies in both yeast and mammalian cells have 
demonstrated that rapamycin inhibits ribosome biogen-
esis. Rapamycin blocks the biosynthesis of ribosomes by 
inhibiting transcription of RNA polymerase I (Pol I)-depen-
dent rRNA genes, Pol II-dependent ribosomal protein 
genes (RP genes), and Pol III-dependent tRNA genes and 
also by inhibiting the processing of 35S rRNA (Martin and 
Hall, 2005). In yeast and mammals, TOR controls Pol I via 
the transcription factor RRN3/TIF1A (Claypool et al., 2004; 
Mayer et al., 2004). TIF1A is an essential Pol I-associated 
initiation factor. Rapamycin treatment leads to TIF1A inac-
tivation and thus impairs formation of the transcription ini-
tiation complex. Furthermore, TIF1A translocates from the 
nucleus to the cytoplasm upon mTOR inactivation by rapa-
mycin (Mayer et al., 2004). Recent studies in yeast have 
identified the forkhead-like transcription factor FHL1 as a 
critical regulator of Pol II-dependent RP gene expression 
(Martin et al., 2004; Schawalder et al., 2004; Wade et al., 
2004). FHL1 is constitutively bound to RP gene promoters 
and is regulated by the two cofactors IFH1 (coactivator) 
and CRF1 (corepressor). TORC1 maintains the corepres-
sor CRF1 in the cytoplasm. Upon TORC1 inactivation, 
CRF1 translocates into the nucleus where it competes with 
the coactivator IFH1 for binding to FHL1, leading to inhi-
bition of RP gene transcription (Martin et al., 2004). TOR 
controls RP genes also via the Zn finger transcription fac-
tor SFP1 that binds and regulates RP gene promoters in 
a TOR-dependent manner (Jorgensen et al., 2004). Addi-
tionally, histone modifying factors affect RP gene expres-
sion and have been implicated as TOR effectors (Hum-
phrey et al., 2004). Thus, TOR links nutrient availability to 
the biosynthesis of ribosomes. The mechanism by which 
TOR controls the activity of all three RNA polymerases in a 
coordinated manner is not understood.
Macroautophagy
Starved cells degrade cytoplasmic contents, including 
organelles, and thereby recycle macromolecules to ensure 
survival under nutrient-impoverished conditions. This 
catabolic process, known as macroautophagy, involves 
the enclosure of cytoplasm by a double-membrane struc-
ture (autophagosome) and its subsequent delivery to 
the vacuole. TOR controls macroautophagy in yeast and higher eukaryotes (Lum et al., 2005). In yeast, TOR nega-
tively controls macroautophagy via inhibition of the protein 
kinase ATG1 that mediates an early activation step in the 
autophagic process (Kamada et al., 2000). In Drosophila, 
dTOR mutant larvae display constitutive macroautophagy 
in the fat body, and starvation-induced macroautophagy 
is suppressed by constitutively active dTOR (Scott et al., 
2004). The protective role of macroautophagy during star-
vation is underscored by the finding that inhibition of mac-
roautophagy enhances the severity of the dTOR loss-of-
function mutant phenotype (Scott et al., 2004). dTOR also 
regulates macroautophagy in response to hormonal fac-
tors during Drosophila development (Rusten et al., 2004). 
Similar to yeast TOR, Drosophila dTOR suppresses macro-
autophagy by a mechanism that involves ATG1.
TOR controls not only bulk protein degradation by mac-
roautophagy, but also the ubiquitination, internalization, and 
turnover of specific nutrient transporters. In yeast, TORC1 
prevents the turnover of amino acid and glucose transport-
ers (Schmelzle et al., 2004 and references therein). Simi-
larly, mTORC1 controls trafficking of nutrient transporters 
and thereby promotes uptake of nutrients such as glucose, 
amino acids, lipoprotein, and iron (Edinger and Thompson, 
2002). In support of these findings, mTOR was identified in 
a kinome-wide screen for regulators of membrane traffick-
ing in mammalian cells (Pelkmans et al., 2005).
Transcription
The nuclear localization and the activity of several nutri-
ent- and stress-responsive transcription factors in yeast 
are regulated by TORC1-mediated phosphorylation (Loe-
with and Hall, 2004). mTORC1 signaling also controls 
transcription of many genes, particularly genes involved 
in metabolic and biosynthetic pathways, as demonstrated 
by microarray experiments on rapamycin-treated mamma-
lian cells (Peng et al., 2002). TOR-dependent transcription 
programs may be regulated through URI (unconventional 
prefoldin RPB5 interactor; Gstaiger et al., 2003). URI is 
involved in the regulation of nutrient-sensitive, TORC1-con-
trolled transcription pathways in yeast and mammals. It 
interacts with all three RNA polymerases through a shared 
subunit and is phosphorylated in a TOR-dependent man-
ner. In addition, ribosome biogenesis is controlled at the 
level of rDNA transcription by mTOR through the transcrip-
tion factors UBF and TIF1A (Hannan et al., 2003; Mayer 
et al., 2004). Thus, mTOR also regulates nutrient-respon-
sive transcription programs. Furthermore, mTOR has been 
demonstrated to phosphorylate STAT1 and STAT3 (signal 
transducer and activator of transcription; Kristof et al., 
2003 and references therein) and to activate the nuclear 
receptor PPARγ (see below), in a rapamycin-sensitive man-
ner. The role of mTOR-controlled transcription in mediating 
cell growth remains poorly understood.
Actin Organization
Early studies established a role for TOR in the organization 
of the actin cytoskeleton (Loewith and Hall, 2004). In yeast, 
rapamycin-insensitive TORC2 controls the cell cycle-depen-
dent polarization of the actin cytoskeleton. TORC2 signals to 
the actin cytoskeleton by activating a Rho1 GTPase switch. Cell 124, February 10, 2006 ©2006 Elsevier Inc. 477
Upon activation, Rho1 interacts with and activates PKC1, 
which in turn signals to the actin cytoskeleton via a MAP 
kinase pathway. How TORC2 regulates the Rho1 GTPase 
switch is not completely understood but might involve 
SLM1/2 and YPK2, two recently identified substrates of 
TORC2 (Audhya et al., 2004; Fadri et al., 2005; Kamada et 
al., 2005), in addition to the Rho1 exchange factor ROM2 
(Loewith and Hall, 2004). The PH domain-containing pro-
teins SLM1 and SLM2 act downstream of TORC2 and the 
phosphatidylinositol-4-phosphate 5-kinase MSS4 to regu-
late actin organization. YPK2, the yeast homolog of SGK1 
(serum- and glucocorticoid-activated kinase), belongs to the 
AGC family of protein kinases. YPK2 requires phosphoryla-
tion in a hydrophobic motif and in the T loop of the catalytic 
domain for its activation. Phosphorylation of the hydropho-
bic motif is mediated by TORC2, whereas phosphorylation 
of the T loop is mediated by PKH2 (yeast homolog of PDK1), 
which acts downstream of sphingolipids in yeast. Thus, 
YPK2 integrates TORC2 and PKH-mediated sphingolipid 
signals to control actin polarization. It is currently unknown 
whether SLM1/2 or YPK2 signal through Rho1 or through a 
parallel pathway to the actin cytoskeleton.
mTORC2 also signals to the actin cytoskeleton (Jacinto 
et al., 2004; Sarbassov et al., 2004). Although the direct 
targets of mTORC2 that mediate signaling to the actin 
cytoskeleton are unknown, mTORC2 signaling to the actin 
cytoskeleton may involve PKCα and the small GTPases 
Rho and Rac. The recent finding that TORC2 exists in 
Dictyostelium where it is also required for cell polarity 
further supports the notion that TORC2 signaling is 
functionally conserved (Lee et al., 2005).
Metabolism
TOR controls many aspects of cellular metabolism including 
amino acid biosynthesis, glucose homeostasis, and others 
(see above; Thomas et al., 2004). Recent studies suggest 
that the TOR signaling network also controls fat metabolism. 
In particular, mTORC1 appears to play an important role in 
adipogenesis as rapamycin treatment prevents adipocyte 
differentiation and, thus, lipid accumulation (Kim and Chen, 
2004 and references therein). The mechanism by which 
mTOR controls adipogenesis is poorly understood but might 
involve the nuclear receptor PPARγ, as rapamycin treatment 
inhibits PPARγ activity (Kim and Chen, 2004). PPARγ plays 
a critical role in adipogenesis and lipid accumulation and is 
therefore referred to as one of the so-called “thrifty genes” 
that are responsible for efficient storage of energy (Lazar, 
2005 and references therein). The regulation of fat metab-
olism by mTORC1 also involves signaling via S6K1. S6K1 
mutant mice display reduced adipose tissue and a decrease 
in fat accumulation due to enhanced β oxidation (Um et al., 
2004). Furthermore, melted mutant flies, which are defective 
in TOR signaling, are lean due to loss of fat (Teleman et al., 
2005). Thus, loss of TOR activity correlates with a decrease 
in fat accumulation, suggesting that the TOR pathway may 
be a “thrifty pathway” normally required for fat accumula-
tion. Interestingly, in addition to being a passive fat-storage 
depot, adipose tissue is also an active organ that secretes 
hormones that regulate appetite and other aspects of animal 478 Cell 124, February 10, 2006 ©2006 Elsevier Inc.physiology, suggesting that there might be broader implica-
tions to the control of adipogenesis by mTOR. Thus, mTOR 
may play a role in the development of metabolic disorders 
such as obesity and type 2 diabetes.
Regulatory Loops: Intricacies of the TOR Network
Negative Regulation of IRS by S6K1
Recent studies have highlighted the existence of a negative 
feedback loop from the nutrient-sensitive TSC-mTOR-S6K1 
pathway to the upstream, insulin-responsive IRS-PI3K-PDK1-
Akt pathway (Figure 2; Harrington et al., 2004; Shah et al., 
2004; Um et al., 2004). Earlier studies showed that increased 
amino acid availability can inhibit signaling through the insu-
lin pathway (Tremblay et al., 2005). The rapamycin sensitivity 
of this effect suggested that the inhibition is mediated by a 
negative feedback loop from mTOR to a component of the 
insulin pathway. This model was supported and extended 
by more recent studies showing that loss of TSC1 or TSC2, 
in mouse embryonic fibroblasts (MEFs) or Drosophila, leads 
to a strong inhibition of insulin-mediated PI3K signaling 
(Manning, 2004). TSC-mTOR-S6K1 signaling attenuates 
PI3K by phosphorylation and inactivation of IRS proteins. In 
particular, S6K1 regulates IRS1 both at the transcriptional 
level and through direct phosphorylation, thereby impairing 
IRS1 adaptor function (Um et al., 2004). Thus, constitutive 
activation of mTOR-S6K1 signaling induces a negative feed-
back loop to attenuate PI3K via inhibition of IRS.
S6K1 knockout mice, due to loss of IRS inhibition, are 
hypersensitive to insulin yet do not become hypoglycemic 
(Um et al., 2004). The absence of hypoglycemia is most likely 
due to these mice also having a low mass of β cells and thus 
a low level of insulin. Phosphorylation-deficient S6 knockin 
mice exhibit a nearly identical β cell phenotype, suggesting 
that the β cell defect is due, at least in part, to a failure of 
S6K1 to phosphorylate ribosomal protein S6 (Ruvinsky et 
al., 2005). Curiously, phosphorylation-deficient S6 mice are 
also hypersensitive to insulin, suggesting that S6 may some-
how be involved in the negative feedback loop to IRS.
The feedback inhibition of insulin-PI3K signaling is rel-
evant to the development of metabolic disorders such 
as obesity and diabetes. Under conditions where mTOR 
signaling is inappropriately activated, due to a TSC defi-
ciency or excess of nutrients, the feedback loop damp-
ens the duration and strength of PI3K signaling and thus 
leads to insulin resistance. In addition, the benign nature 
of TSC-related tumors might be explained by the action 
of this negative feedback. Indeed, analyses of tumors in 
heterozygous TSC2 mutant mice revealed that feedback 
inhibition of Akt correlates with limited tumor growth (Ma et 
al., 2005b; Manning et al., 2005).
Regulation of Akt/PKB by mTORC2
mTORC2 was discovered only recently. Thus, the upstream 
regulators and downstream effectors of this rapamycin-
insensitive mTOR complex are largely unknown. mTORC2 
phosphorylates and activates Akt/PKB, another member 
of the AGC protein kinase family (Sarbassov et al., 2005). 
The role of Akt includes regulation of cell proliferation, 
survival, metabolism, and transcription. Through its PH 
Table 2. Summary of Protooncogenes and Tumor Suppressors that Are Functionally Linked to mTORC1 Signaling
Protooncogenes Evidence References
PI3K Aberrantly high PI3K activity has been implicated in cell transformation 
and tumor progression and has been observed in a variety of human 
cancers.
Vivanco and Sawyers, 2002
PKB/Akt Akt is amplified in a subset of human cancers. Vivanco and Sawyers, 2002
Rheb Rheb expression is elevated in many tumor cells, and Rheb may be the 
critical target by which farnesyl transferase inhibitors mediate their antitu-
mor activity.
Basso et al., 2005
ras ras mutations that result in hyperactivation of the protein are among the 
most frequent alterations in human cancers.
Coleman et al., 2004
eIF4E Ectopic overexpression of eIF4E can transform cells ex vivo and in vivo. 
eIF4E is overexpressed in many human tumors.
Bjornsti and Houghton, 2004; 
Ruggero et al., 2004
S6K1 S6K1 is amplified or overexpressed in a large fraction of breast cancers, 
and this correlates with poor prognosis.
Barlund et al., 2000
Tumor Suppressors
PTEN Loss of PTEN function has been found in a large fraction of advanced 
human cancers. Individuals with inherited mutations in PTEN develop 
hamartoma tumor syndromes (Cowden disease, Bannayan-Riley-Ruval-
caba syndrome, Proteus syndrome, Lhermitte-Duclos disease) and are at 
higher risk of developing several types of cancer.
Inoki et al., 2005; Sansal and 
Sellers, 2004; Vignot et al., 2005
TSC1, TSC2 Individuals with mutations in TSC1 or TSC2 develop tuberous sclerosis 
complex (TSC) characterized by the formation of hamartomas in a wide 
variety of organs.
Kwiatkowski, 2003
NF1 Individuals with mutations in NF1 develop neurofibromatosis type 1, char-
acterized by benign and malignant peripheral nerve sheath tumors.
Johannessen et al., 2005
LKB1 Individuals with mutations in LKB1 develop Peutz-Jeghers syndrome, 
characterized by hamartomas in the gastrointestinal tract.
Inoki et al., 2005; Tee and 
Blenis, 2005
p53 p53 performs a variety of antineoplastic activities and is mutated in the 
majority of human tumors.
Sigal and Rotter, 2000
4E-BP1 Overexpression of activated 4E-BP1 blocks c-Myc induced cellular trans-
formation.
Lynch et al., 2004
beclin-1 Decreased expression of beclin-1 (a protein required for autophagy) is as-
sociated with human breast carcinomas, and beclin-1 mutant mice have a 
high frequency of tumor formation.
Lum et al., 2005domain, Akt binds PIP3 generated by PI3K upon stimu-
lation by insulin or insulin-like growth factors. Similar to 
other AGC kinases, membrane bound Akt is activated by 
phosphorylation at two sites, a site in the activation loop 
of the kinase (Thr308) and a site in the hydrophobic motif 
(Ser473). Whereas PDK1 phosphorylates Akt in the activa-
tion loop, the kinase responsible for phosphorylation of the 
hydrophobic site was recently determined to be mTORC2 
(Sarbassov et al., 2005). Thus, mTORC2 performs a posi-
tive role in the activation of Akt. Importantly, Akt is phos-
phorylated by mTORC2 but not by mTORC1. The logic 
of mTORC2 activating Akt remains elusive. Because Akt 
activates mTORC1, mTORC2 could indirectly activate 
mTORC1. However, knockdown of mTORC2 does not 
affect the mTORC1 effector S6K1 (Sarbassov et al., 2004; 
Jacinto et al., 2004), suggesting that mTORC2 activates a 
pool of Akt that is not upstream of mTORC1. In support of 
the finding that mTORC2 is upstream of Akt, TORC2 in Dic-
tyostelium signals to Akt to regulate chemotaxis and cell 
polarity (Lee et al., 2005).Phosphorylation of mTOR by S6K1
mTOR is phosphorylated at Thr2446 and Ser2448. The 
phosphorylation at these two sites was shown to be PI3K 
dependent and increased in response to constitutively 
active Akt. These observations led to the model that Akt 
acts directly on mTOR, in addition to acting indirectly via 
TSC. Two groups have now shown that S6K1, and not 
Akt, is the kinase responsible for phosphorylation of these 
two sites (Chiang and Abraham, 2005; Holz and Blenis, 
2005). The significance of this potential feedback loop is 
unknown as it is not yet clear whether Thr2446/Ser2448 
phosphorylation is a positive, negative, or inconsequential 
modification. It is also unknown whether S6K1 phosphory-
lates mTOR in mTORC1, mTORC2, or both.
TOR and Disease
Cancer and Hamartoma Syndromes
The ongoing elucidation of the signaling components 
upstream and downstream of mTORC1 has suggested a 
causal link between aberrant mTORC1 signaling and tumor Cell 124, February 10, 2006 ©2006 Elsevier Inc. 479
formation. As summarized in Table 2, the signaling com-
ponents upstream and downstream of mTORC1 are fre-
quently altered in a number of human tumors. Specifically, 
aberrantly high mTORC1 activity appears to be an underly-
ing cause of cancers and hamartoma syndromes (Inoki et 
al., 2005; Tee and Blenis, 2005). Hamartoma syndromes, 
which are characterized by benign tumors that contain 
architecturally disorganized but otherwise normally dif-
ferentiated cells, affect a wide variety of tissues, including 
brain, skin, kidneys, heart, lung, and the gastrointestinal 
tract. Although benign, hamartoma syndromes can prog-
ress to malignancy. Notable among the hamartoma syn-
dromes is tuberous sclerosis complex resulting from muta-
tion of TSC1 or TSC2 (Kwiatkowski, 2003). The correlation 
between tumor growth and hyperactive mTORC1 signal-
ing suggests that tumors may be sensitive to mTORC1 
inhibitors. To this end, rapamycin (sirolimus, Wyeth) and 
its derivatives temsirolimus (CCI-779, Wyeth), everolimus 
(RAD-001, Novartis Pharma AG) and AP-23573 (Ariad 
Pharmaceuticals) are currently being evaluated in clinical 
trials as cancer treatments. Preclinical studies suggest that 
sensitivity of tumors to mTORC1 inhibition may correlate 
with aberrant activation of the PI3K pathway and/or with 
aberrant expression of cell cycle regulatory or antiapop-
totic proteins. Clinical trial results show that mTOR inhibi-
tors are generally well tolerated and may induce prolonged 
stable disease and even tumor regressions in a subset of 
patients (Dancey, 2005; Vignot et al., 2005).
Allograft Rejection and Autoimmune Disorders
Rapamycin interferes with the activation of T cells, and 
clinical trials in the late 1990s confirmed the efficacy of 
sirolimus and everolimus as potent immunosuppressive 
agents in renal transplantation. These drugs have also 
shown promise in liver transplantation (sirolimus) and car-
diac transplantation (everolimus), and appear to facilitate 
weaning of patients off nephrotoxic calcineurin inhibitors. 
Sirolimus and everolimus are themselves not without side 
effects. Both drugs present metabolic, hematological, and 
dermatological effects including increases in serum choles-
terol and triglycerides, anemia, skin rashes, and diarrhea. 
Current protocols employ a combination of complemen-
tary agents (e.g., calcineurin inhibitors, mTORC1 inhibitors, 
and steroids) to yield optimal immunosuppression with 
minimal side effects.
The immunosuppressive activity of rapamycin and 
its derivatives suggests that these drugs may also have 
potential in the treatment of autoimmune disorders includ-
ing rheumatoid arthritis, psoriasis, multiple sclerosis, and 
Parkinson’s disease. Indeed, a number of pharmaceutical 
companies are investigating the efficacy of mTORC1 inhibi-
tors in treating these autoimmune disorders (reviewed in 
Young and Nickerson-Nutter, 2005).
Cardiovascular Disease
Cardiovascular disease is a leading killer in the developed 
world. In the year 2000, more than 1,000,000 percutane-
ous transluminal coronary procedures were performed in 
the US, and about half of these included the placement 
of intracoronary stents (an expandable metal coil that is 480 Cell 124, February 10, 2006 ©2006 Elsevier Inc.inserted into the newly opened area of the artery to keep 
the artery from narrowing or closing again). Although stent-
ing brings long-term benefit to a majority of patients, a 
substantial number of patients experience overgrowth of 
smooth muscle cells surrounding the stent, similar to scar 
tissue, and reblockage of the artery (in-stent restenosis). 
A number of approaches have been employed to reduce 
the incidence of in-stent restenosis, ranging from systemic 
pharmacologic treatments to modification of the compo-
sition of the stent. Drug-eluting stents have shown much 
promise in this regard. A drug that inhibits cell growth is 
attached to the metal of a stent, and an outer layer of bio-
compatible polymers allows the drug to elute over an  30 
day period. Paclitaxel- and sirolimus-eluting stents have 
been analyzed in a number of clinical trials and both have 
been found to improve patient outcome (Gershlick, 2005). 
Future clinical studies will evaluate stents that elute differ-
ent drugs (including other rapamycin derivatives) at differ-
ent release kinetics.
Cardiac hypertrophy is also a major risk factor for heart 
failure. Overgrowth of cardiomyocytes is dependent on the 
PI3K-mTORC1 pathway (reviewed in Inoki et al., 2005; Tee 
and Blenis, 2005). Furthermore, inherited mutations in the 
gene encoding AMPKγ2, a regulatory subunit of AMPK, 
result in reduced AMPK activity and cause familial hyper-
trophic cardiomyopathy and Wolff-Parkinson-White syn-
drome, presumably via hyperactivation of mTORC1. These 
observations suggest that mTORC1 inhibitors may be use-
ful therapeutic agents for the treatment of lifestyle-induced 
and inherited cardiac hypertrophy.
Metabolic Disorders
Both type 2 diabetes and obesity, among other disorders, 
are associated with an inability to respond to insulin (insulin 
resistance). Recent studies (reviewed in Manning, 2004) 
have demonstrated that inhibition of IRS protein function 
is one means by which cells become desensitized to insu-
lin. As described above, one mechanism by which IRS 
function is inhibited is via a negative feedback loop from 
mTOR-S6K. This suggests that mTORC1 inhibitors may be 
effective for the treatment of metabolic disorders involving 
insulin resistance.
Future Directions
Ongoing clinical trials indicate that mTORC1 inhibitors 
show remarkable clinical potential in a variety of disease 
settings. However, major questions concerning the design 
of these clinical trials and in particular the future of mTORC1 
inhibitors as anticancer agents remain. For example, what 
distinguishes a cancer that is likely to respond favorably 
to mTORC1 inhibition from a cancer that will not respond 
favorably? To answer this question, we must fully under-
stand the pathways that regulate mTORC1 and how these 
pathways are altered in disease. This includes a full under-
standing of the consequences that mTORC1 inhibition will 
have on Akt signaling. For example, will mTORC1 inhibi-
tion prevent the negative feedback loop from S6K to IRS 
(and ultimately to Akt) and thereby exacerbate some can-
cers? Additionally, the anticancer capabilities of mTORC1 
inhibitors appear to be augmented when used in combina-
tion with other anticancer agents (Beuvink et al., 2005). 
What additional pathways should be targeted for optimal 
response? Also lacking is an understanding of how nutri-
ent abundance/quality is sensed and signaled to mTORC1. 
Studies in yeast, worms, flies, and mammals have all linked 
nutrient status to mTORC1 activity, and yet the relevant 
sensing mechanisms remain obscure.
It is also important to note that mTORC1 inhibition has 
relied almost exclusively on rapamycin or closely related 
derivatives of rapamycin. However, the mechanism of 
action of these compounds is poorly understood, and 
therefore the existence of medically relevant, rapamycin-
insensitive mTORC1 substrates cannot be ruled out. Con-
versely, the generation of novel mTORC1 inhibitors that 
interrupt specific mTORC1-substrate interactions may be 
just as efficacious as rapamycins but present fewer side 
effects. FKBP12-rapamycin is probably the most potent 
and specific kinase inhibitor known (Davies et al., 2000). 
A better understanding of the mode of action of FKBP12-
rapamycin action could lead to the development of potent 
and specific inhibitors of other kinases.
It is estimated that up to one-third of proteins in a cell are 
phosphorylated, many at multiple sites. The existence of 
roughly 600 kinases in the human kinome implies that each 
human kinase phosphorylates on average  20 substrates. 
Identification of mTORC substrates will be crucial to under-
stand the mechanisms by which TORCs control growth. 
As noted in Table 2, pathways downstream of mTORC1 
are also believed to have important roles in tumorigenesis. 
What are the critical substrates of mTORC1 for tumor for-
mation? These effectors may themselves serve as poten-
tial drug targets. The molecular characterization of down-
stream pathways may also facilitate the development of 
molecular markers useful for diagnosis and prognosis and 
to monitor biological effects of mTORC1 inhibitors.
The specific functions of mTOR-associated proteins 
remain to be determined. Tissue-specific disruptions of 
mTORC1 and mTORC2 will be important to define when 
and where mTORC functions are needed. This is particu-
larly interesting given the extreme toxicity of rapamycin in 
early embryos versus the relatively mild affects of rapamy-
cin in adults. These studies may suggest additional settings 
where mTORC inhibitors/agonists may be of use. Possibili-
ties include enhancement of life span or treatment of cog-
nitive disorders. The clinical efficacies of mTORC1 inhibi-
tors as agents for the treatment of metabolic disorders and 
cardiac hypertrophy also remain to be evaluated.
Lastly, the existence of rapamycin-insensitive mTORC2 
has important implications in mTOR biology. Cellular pro-
cesses that are unaltered by rapamycin treatment are not 
necessarily mTOR independent. Furthermore, it appears 
that growth factors may regulate mTORC2 (Jacinto et al., 
2004; Sarbassov et al., 2005), but whether this involves the 
same signaling cascades that regulate mTORC1 remains 
to be determined. If mTORC2 indeed shares upstream 
regulators with mTORC1, does mTORC2 signaling con-
tribute to the pathology of diseases so far attributed solely to mTORC1 hyperactivity? For example, does hyperactive 
mTORC2, via altered regulation of the actin cytoskeleton, 
cause the morphological changes observed in hamartoma 
cells? The recent observation that mTORC2 regulates Akt 
also suggests that, as is the case for mTORC1, mTORC2 
dysregulation and/or chemical inhibition may be clinically 
relevant. Finally, how does TORC2 signaling, in mamma-
lian and nonmammalian systems, contribute to the control 
of normal physiological processes that were previously 
ascribed solely to TORC1? For example, does the con-
trol of lifespan, memory, or fat metabolism by TOR involve 
TORC2 in addition to TORC1? Although our understanding 
of TOR signaling has come a long way since the fateful col-
lection of soil on Easter Island three decades ago, much 
remains unknown.
Note on Nomenclature
mLST8 is referred to in the literature as either mLST8 or GβL, due to 
it having been identified as an mTOR binding protein in two indepen-
dent studies (Loewith et al., 2002; Kim et al., 2003). Similarly, rictor 
is referred to as either rictor or mAVO3, also because it was demon-
strated to bind mTOR by two independent studies (Sarbassov et al., 
2004; Jacinto et al., 2004). To avoid further confusion in the literature, 
we propose that the field adopt mLST8 and rictor as the official names 
for these two proteins. These are the names used in the first of the two 
binding studies that were published for each protein (Loewith et al., 
2002; Sarbassov et al., 2004). This proposal applies only to the mam-
malian orthologs. The nomenclature of the nonmammalian orthologs is 
unambiguous, and these proteins should continue to be referred to by 
their current names (see Table 1). Finally, given the diversity of names 
for TOR-associated proteins from different species, we urge use of 
TORC1 and TORC2 (mTORC1, etc.) as a standardized nomenclature 
for the complexes.
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